Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1980 1
1981 2
1982 1
1983 1
1984 1
1988 2
1989 2
1990 1
1991 3
1992 3
1993 2
1994 5
1995 1
1996 1
1998 1
1999 2
2000 4
2002 1
2004 2
2005 9
2006 5
2007 5
2008 4
2009 11
2010 5
2011 12
2012 10
2013 9
2014 12
2015 17
2016 14
2017 22
2018 25
2019 17
2020 22
2021 34
2022 28
2023 25
2024 30
2025 33
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for radio mb
Search for Rodio MB instead (2 results)
CAR/CSACI Practice Guidance for Contrast Media Hypersensitivity.
Byrne A, Macdonald DB, Kirkpatrick IDC, Pham M, Green CR, Copaescu AM, McInnes MDF, Ling L, Ellis A, Costa AF. Byrne A, et al. Can Assoc Radiol J. 2025 Aug;76(3):400-416. doi: 10.1177/08465371241311253. Epub 2025 Jan 11. Can Assoc Radiol J. 2025. PMID: 39797723 Free article. Review.
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelínek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Mateos MV, et al. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949. Blood Adv. 2025. PMID: 40763276 Free PMC article. Clinical Trial.
Cellular immunotherapy for medulloblastoma.
Schakelaar MY, Monnikhof M, Crnko S, Pijnappel EW, Meeldijk J, Ten Broeke T, Bovenschen N. Schakelaar MY, et al. Neuro Oncol. 2023 Apr 6;25(4):617-627. doi: 10.1093/neuonc/noac236. Neuro Oncol. 2023. PMID: 36219688 Free PMC article. Review.
Medulloblastoma (MB) is the most common malignant brain tumor in children, making up ~20% of all primary pediatric brain tumors. ...In addition, we compare our findings to cellular immunotherapy in glioma, an MB-like intracranial tumor. Finally, future possibilities …
Medulloblastoma (MB) is the most common malignant brain tumor in children, making up ~20% of all primary pediatric brain tumors. ...I …
Radio-sensitization by Piper longumine of human breast adenoma MDA-MB-231 cells in vitro.
Yao JX, Yao ZF, Li ZF, Liu YB. Yao JX, et al. Asian Pac J Cancer Prev. 2014;15(7):3211-7. doi: 10.7314/apjcp.2014.15.7.3211. Asian Pac J Cancer Prev. 2014. PMID: 24815473 Free article.
BACKGROUND: The current study investigated the effects of Piper longumine on radio-sensitization of human breast cancer MDA-MB-231 cells and underlying mechanisms. ...CONCLUSIONS: Piper longumine at a non-cytotoxic concentration can enhance the radio-sensitiv …
BACKGROUND: The current study investigated the effects of Piper longumine on radio-sensitization of human breast cancer MDA-MB …
Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies.
Lu Z, Verginadis I, Kumazoe M, Castillo GM, Yao Y, Guerra RE, Bicher S, You M, McClung G, Qiu R, Xiao Z, Miao Z, George SS, Beiting DP, Nojiri T, Tanaka Y, Fujimura Y, Onda H, Hatakeyama Y, Nishimoto-Ashfield A, Bykova K, Guo W, Fan Y, Buynov NM, Diehl JA, Stanger BZ, Tachibana H, Gade TP, Puré E, Koumenis C, Bolotin EM, Fuchs SY. Lu Z, et al. Sci Transl Med. 2024 Aug 21;16(761):eadn0904. doi: 10.1126/scitranslmed.adn0904. Epub 2024 Aug 21. Sci Transl Med. 2024. PMID: 39167664 Free PMC article.
Moreover, inclusion of dCNP into the chemo-, radio-, or immune-therapeutic regimens increased their efficacy against solid tumors in immunocompetent mice. ...
Moreover, inclusion of dCNP into the chemo-, radio-, or immune-therapeutic regimens increased their efficacy against solid tumors in …
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free PMC article. Clinical Trial.
Baicalein Suppresses Stem Cell-Like Characteristics in Radio- and Chemoresistant MDA-MB-231 Human Breast Cancer Cells through Up-Regulation of IFIT2.
Koh SY, Moon JY, Unno T, Cho SK. Koh SY, et al. Nutrients. 2019 Mar 14;11(3):624. doi: 10.3390/nu11030624. Nutrients. 2019. PMID: 30875792 Free PMC article.
We established treatment-resistant TNBC MDA-MB-231/IR cells by irradiating the parental MDA-MB-231 cells 25 times with 2 Gy irradiation and investigated the molecular mechanisms of acquired resistance. The resistant MDA-MB-231/IR cells were enhanced in migrat …
We established treatment-resistant TNBC MDA-MB-231/IR cells by irradiating the parental MDA-MB-231 cells 25 times with 2 Gy ir …
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.
Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, Sakthivel S, Sharon I, Bernard A, Pelletier S, Ripstein Y, Spatz A, Miller WH, Jamal R, Lapointe R, Mes-Masson AM, Petrecca K, Meguerditchian AN, Richardson K, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Schmeing TM, Rodier F, Turcotte S, Mihalcioiu C, Meterissian S, Watson IR. Berry D, et al. Cell Rep. 2025 Mar 25;44(3):115365. doi: 10.1016/j.celrep.2025.115365. Epub 2025 Mar 1. Cell Rep. 2025. PMID: 40023845 Free article.
FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma.
Beffinger M, Schellhammer L, Taskoparan B, Deplazes S, Salazar U, Tatari N, Seehusen F, von Balthazar L, Zinner CP, Spath S, Shekarian T, Ritz MF, McDaid M, Egloff P, Zimmermann I, Okada H, Ward ES, Rohrer J, Seeger MA, Buch T, Hutter G, Vom Berg J. Beffinger M, et al. Nat Commun. 2025 May 22;16(1):4751. doi: 10.1038/s41467-025-59971-0. Nat Commun. 2025. PMID: 40404625 Free PMC article.
In murine glioblastoma, FcRn-silenced IL-12Fc induces more durable responses with negligible systemic cytokine exposure and boosts the efficacy of radio- and chemotherapy. It triggers anti-tumor responses independently of peripheral T cell influx or lymphopenia and leads t …
In murine glioblastoma, FcRn-silenced IL-12Fc induces more durable responses with negligible systemic cytokine exposure and boosts the effic …
357 results